Cardiovascular, Renal & Metabolic Diseases

A world of comprehensive and close care for patients with CVRM diseases

At AstraZeneca, CVRM (cardiovascular, renal and metabolic) diseases are one of our main therapeutic areas because science continues to discover common aspects between metabolism, heart failure, arteriopathies and kidney diseases — four distinct but closely interrelated. Whereas shared risk factors are often currently neither diagnosed nor addressed, science suggests that, by considering common mechanisms of CVRM diseases, we can work with healthcare practitioners (HCPs) to improve outcomes in patients with one specific diagnosis before co-morbidities emerge.

We follow science to develop innovative treatments and ultimately modify or even stop the natural course of disease and regenerate organs. Together with key experts from around the world, we are collaborating to accelerate our scientific progress and to better define the patient populations that can benefit from the new cardio-renal-metabolic therapies that we are developing.

Pablo Cardoza CVRM Business Unit Director

More than 20 million people die each year from cardiovascular, kidney and metabolic diseases1 but, despite the close relationship between these diseases, the risk factors they share are often not diagnosed or treated2. For example, if you are an adult with diabetes, your risk of hospitalization for a heart attack might be 1.8 times higher than that of an adult without diabetes3. Studying the combined effect of diabetes and kidney diseases, life expectancy can be reduced up to 15 years in men and 16 years in women.4

Our mission is to help protect more people from the often fatal consequences of CVRM diseases by 2025. We work with science-driven, research-driven cardiovascular, kidney and diabetes experts around the world to implement a proactive, collaborative, comprehensive and multidisciplinary approach to patient care.

We focus on unmet needs


In 2015, there were approximately 111 million cases of ischemic heart disease worldwide, and cardiovascular diseases are the leading cause of death in the world: approximately 7.9 million people die every year.5, 6

Heart failure

There are 64 million patients worldwide with heart failure and many have at least one underlying condition, such as type 2 diabetes.7.8

Kidney diseases

Chronic kidney disease (CKD) can be a complex and disabling disease. It is estimated that there are about 200 million adults diagnosed worldwide.9

Metabolic diseases

Diabetes is a disease with an increasing prevalence and carries a tremendous global burden. It is currently projected to affect more than 629 million people in 2045.10


1. Wang H et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388(10053):1459–544.

2. Edelman Intelligence Relevance and barriers amongst EU specialists Survey 2018. Document ID: Z2-0050 | Date of preparation: August 2018 | Date of expiry: July 2020

3. Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report, 2014: Centers for Disease Control and Preventions Division of Diabetes Translation [cited 2018 Jul 25]. Available from: URL: 

4. Wen CP et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int 2017; 92(2):388–96.

5. World Health Organization. WHO World Heart Day: Scale up prevention of heart attack and stroke: World Health Organization; 2019 [cited 2019 Feb 19]. Available from: URL:

6. Roth GA et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol 2017; 70(1):1–25.

7. Vos T et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017; 390(10100):1211–59.

8. Lawson CA et al. Comorbidity health pathways in heart failure patients: A sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. PLoS Med 2018; 15(3):e1002540.

9. Ojo A. Addressing the global burden of chronic kidney disease through clinical and translational research. Trans Am Clin Climatol Assoc 2014; 125:229-43; discussion 243-6.

10. Ogurtsova K et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128:40–50.

11. AstraZeneca global, [cited april 2019]. Available from: URL: